{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:22:09Z","timestamp":1790680929099,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Disease recurrence after therapy, due to the persistence of resistant leukemic cells, represents a fundamental problem in the treatment of leukemia. Elucidating the mechanisms responsible for the maintenance of leukemic cells, before and after treatment, is therefore critical to identify curative modalities. It has become increasingly clear that cell-autonomous mechanisms are not solely responsible for leukemia maintenance. Here, we report a role for Pml in mesenchymal stem cells (MSCs) in supporting leukemic cells of both CML and AML. Mechanistically, we show that Pml regulates pro-inflammatory cytokines within MSCs, and that this function is critical in sustaining CML-KLS and AML ckit<jats:sup>+<\/jats:sup> leukemic cells non-cell autonomously.<\/jats:p>","DOI":"10.1038\/s41467-017-02427-x","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T17:32:53Z","timestamp":1514568773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche"],"prefix":"10.1038","volume":"9","author":[{"given":"Jlenia","family":"Guarnerio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes Maria","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archita Venugopal","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-9735","authenticated-orcid":false,"given":"Keisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-5295","authenticated-orcid":false,"given":"Pier Paolo","family":"Pandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"2427_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","volume":"121","author":"SJ Forman","year":"2013","unstructured":"Forman, S. J. & Rowe, J. M. The myth of the second remission of acute leukemia in the adult. Blood 121, 1077\u20131082 (2013).","journal-title":"Blood"},{"key":"2427_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrc1592","volume":"5","author":"BJ Huntly","year":"2005","unstructured":"Huntly, B. J. & Gilliland, D. G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 5, 311\u2013321 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"2427_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood-2014-03-563304","volume":"125","author":"Y Aoki","year":"2014","unstructured":"Aoki, Y. et al. Identification of CD34 + and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood 125, 967\u2013980 (2014).","journal-title":"Blood"},{"key":"2427_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818\u2013822 (2006).","journal-title":"Nature"},{"key":"2427_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.stem.2012.01.004","volume":"10","author":"KD Gibbs Jr.","year":"2012","unstructured":"Gibbs, K. D. Jr. et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 10, 210\u2013217 (2012).","journal-title":"Cell Stem Cell"},{"key":"2427_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/nm.3364","volume":"19","author":"DS Krause","year":"2013","unstructured":"Krause, D. S. et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat. Med. 19, 1513\u20131517 (2013).","journal-title":"Nat. Med."},{"key":"2427_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.stem.2014.06.020","volume":"15","author":"M Hanoun","year":"2014","unstructured":"Hanoun, M. et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell 15, 365\u2013375 (2014).","journal-title":"Cell Stem Cell"},{"key":"2427_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852\u2013857 (2010).","journal-title":"Nature"},{"key":"2427_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature19801","volume":"538","author":"ED Hawkins","year":"2016","unstructured":"Hawkins, E. D. et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 538, 518\u2013522 (2016).","journal-title":"Nature"},{"key":"2427_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","volume":"13","author":"K Schepers","year":"2013","unstructured":"Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285\u2013299 (2013).","journal-title":"Cell Stem Cell"},{"key":"2427_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud, D. et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661\u2013673 (2011).","journal-title":"Cancer Cell"},{"key":"2427_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","volume":"25","author":"CW Duan","year":"2014","unstructured":"Duan, C. W. et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell 25, 778\u2013793 (2014).","journal-title":"Cancer Cell"},{"key":"2427_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner, R. S. et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27, 671\u2013681 (2015).","journal-title":"Cancer Cell"},{"key":"2427_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","volume":"6","author":"BJ Huntly","year":"2004","unstructured":"Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587\u2013596 (2004).","journal-title":"Cancer Cell"},{"key":"2427_CR15","first-page":"1285","volume":"6","author":"PP Pandolfi","year":"1991","unstructured":"Pandolfi, P. P. et al. Structure and origin of the acute promyelocytic leukemia myl\/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6, 1285\u20131292 (1991).","journal-title":"Oncogene"},{"key":"2427_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0092-8674(91)90113-D","volume":"66","author":"H de The","year":"1991","unstructured":"de The, H. et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675\u2013684 (1991).","journal-title":"Cell"},{"key":"2427_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0092-8674(91)90112-C","volume":"66","author":"A Kakizuka","year":"1991","unstructured":"Kakizuka, A. et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66, 663\u2013674 (1991).","journal-title":"Cell"},{"key":"2427_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(02)00626-8","volume":"108","author":"P Salomoni","year":"2002","unstructured":"Salomoni, P. & Pandolfi, P. P. The role of PML in tumor suppression. Cell 108, 165\u2013170 (2002).","journal-title":"Cell"},{"key":"2427_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fonc.2014.00023","volume":"4","author":"R Bernardi","year":"2014","unstructured":"Bernardi, R. & Pandolfi, P. P. A dialog on the first 20 years of PML research and the next 20 ahead. Front. Oncol. 4, 23 (2014).","journal-title":"Front. Oncol."},{"key":"2427_CR20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nature07016","volume":"453","author":"K Ito","year":"2008","unstructured":"Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072\u20131078 (2008).","journal-title":"Nature"},{"key":"2427_CR21","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.2882","volume":"18","author":"K Ito","year":"2012","unstructured":"Ito, K. et al. A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18, 1350\u20131358 (2012).","journal-title":"Nat. Med."},{"key":"2427_CR22","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1084\/jem.20091046","volume":"206","author":"S Morikawa","year":"2009","unstructured":"Morikawa, S. et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. 206, 2483\u20132496 (2009).","journal-title":"J. Exp. Med."},{"key":"2427_CR23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.stemcr.2014.04.002","volume":"2","author":"J Guarnerio","year":"2014","unstructured":"Guarnerio, J. et al. Bone marrow endosteal mesenchymal progenitors depend on HIF factors for maintenance and regulation of hematopoiesis. Stem Cell Rep. 2, 794\u2013809 (2014).","journal-title":"Stem Cell Rep."},{"key":"2427_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-032712-095919","volume":"31","author":"PS Frenette","year":"2013","unstructured":"Frenette, P. S., Pinho, S., Lucas, D. & Scheiermann, C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 31, 285\u2013316 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"2427_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature12612","volume":"502","author":"Y Kunisaki","year":"2013","unstructured":"Kunisaki, Y. et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502, 637\u2013643 (2013).","journal-title":"Nature"},{"key":"2427_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","volume":"16","author":"K Schepers","year":"2015","unstructured":"Schepers, K., Campbell, T. B. & Passegue, E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell 16, 254\u2013267 (2015).","journal-title":"Cell Stem Cell"},{"key":"2427_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2013.12.016","volume":"14","author":"LM Kats","year":"2014","unstructured":"Kats, L. M. et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 14, 329\u2013341 (2014).","journal-title":"Cell Stem Cell"},{"key":"2427_CR28","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1101\/gad.1940710","volume":"24","author":"Z Zhao","year":"2010","unstructured":"Zhao, Z. et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 24, 1389\u20131402 (2010).","journal-title":"Genes Dev."},{"key":"2427_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1101\/gad.1771409","volume":"23","author":"J Zuber","year":"2009","unstructured":"Zuber, J. et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23, 877\u2013889 (2009).","journal-title":"Genes Dev."},{"key":"2427_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye, H. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23\u201337 (2016).","journal-title":"Cell Stem Cell"},{"key":"2427_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.prp.2012.06.009","volume":"208","author":"BK Khandany","year":"2012","unstructured":"Khandany, B. K. et al. Evaluation of circulating concentrations of CXCL1 (Gro-alpha), CXCL10 (IP-10) and CXCL12 (SDF-1) in ALL patients prior and post bone marrow transplantation. Pathol. Res. Pract. 208, 615\u2013619 (2012).","journal-title":"Pathol. Res. Pract."},{"key":"2427_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","volume":"61","author":"B Sanchez-Correa","year":"2013","unstructured":"Sanchez-Correa, B. et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 61, 885\u2013891 (2013).","journal-title":"Cytokine"},{"key":"2427_CR33","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","volume":"125","author":"C Schinke","year":"2015","unstructured":"Schinke, C. et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 125, 3144\u20133152 (2015).","journal-title":"Blood"},{"key":"2427_CR34","doi-asserted-by":"crossref","unstructured":"Chen et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat. Gen. doi:10.1038\/s41588-017-0027-2 (2018).\u00a0","DOI":"10.1038\/s41588-017-0027-2"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02427-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T01:20:37Z","timestamp":1671758437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02427-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["2427"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-02427-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]},"assertion":[{"value":"21 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}